Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus

There is a strong interplay between nonalcoholic fatty liver disease (NAFLD), obesity, insulin resistance, and type II diabetes mellitus (T2DM). Liraglutide, a glucagon-like-peptide-1 (GLP-1) analogue, is FDA approved for T2DM in children 10 years or older and more recently approved for chronic weig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohut, Taisa, Panganiban, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191552/
https://www.ncbi.nlm.nih.gov/pubmed/37206449
http://dx.doi.org/10.1097/PG9.0000000000000141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191552/
https://www.ncbi.nlm.nih.gov/pubmed/37206449
http://dx.doi.org/10.1097/PG9.0000000000000141

Ejemplares similares